{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:32:02Z","timestamp":1715974322550},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T00:00:00Z","timestamp":1445990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Insys Therapeutics, Inc., Chandler, Arizona, U.S.A"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To further describe effective dose titration of fentanyl sublingual spray to treat breakthrough cancer pain (BTCP) during the 26\u2010day open\u2010label titration phase of a phase 3, randomized, double\u2010blind, placebo\u2010controlled study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Opioid\u2010tolerant patients with 1 to 4 episodes of BTCP per day were enrolled. For randomization into double\u2010blind treatment, patients must have titrated to a dose (100 to 1,600 mcg) providing effective analgesia for 2 consecutive BTCP episodes. The Treatment Satisfaction Questionnaire for Medication was administered at baseline and at titration end and included a Global Satisfaction domain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 130 patients undergoing titration, 98 (75%) achieved pain relief (median dose = 800 mcg). The most common doses that allowed for adequate pain relief were 800 mcg (24.5%) and 1,200 mcg (20.4%). Of 32 (25%) patients who withdrew from the study, only 3 (2.3%) did not achieve an effective dose. In patients attaining an effective dose, mean Global Satisfaction increased from 54.9 \u00b1 2.1 at baseline to 75.3 \u00b1 1.7 at the end of the titration phase. Seventy\u2010eight patients (60%) reported \u2265 1 adverse event (AE). Thirty\u2010three AEs (25.4%) were considered probably related to treatment, with nausea (6.2%) and somnolence (4.6%) most commonly reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In patients with BTCP, fentanyl sublingual spray can be rapidly and safely titrated to an effective dose, resulting in greater satisfaction with fentanyl sublingual spray than previous BTCP medications.<\/jats:p><\/jats:sec>","DOI":"10.1111\/papr.12360","type":"journal-article","created":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T12:40:16Z","timestamp":1446036016000},"page":"1012-1018","source":"Crossref","is-referenced-by-count":3,"title":["Effective Dose Titration of Fentanyl Sublingual Spray in Patients With Breakthrough Cancer Pain"],"prefix":"10.1111","volume":"16","author":[{"given":"Richard","family":"Rauck","sequence":"first","affiliation":[{"name":"Carolinas Pain Institute and The Center for Clinical Research Winston Salem North Carolina U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Bull","sequence":"additional","affiliation":[{"name":"Four Seasons Hospice and Palliative Care Flat Rock North Carolina U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Parikh","sequence":"additional","affiliation":[{"name":"Insys Therapeutics, Inc. Chandler Arizona U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Dillaha","sequence":"additional","affiliation":[{"name":"Insys Therapeutics, Inc. Chandler Arizona U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Stearns","sequence":"additional","affiliation":[{"name":"The Center for Pain and Supportive Care Scottsdale Arizona U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,10,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(90)90004-W"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1191\/0269216304pm890oa"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2010.0009"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00006-8"},{"key":"e_1_2_9_6_1","first-page":"4","article-title":"Breakthrough cancer pain (BTcP): from definitions to patient burden","volume":"17","author":"Zeppetella G","year":"2010","journal-title":"Eur J Palliat Care"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(00)00161-5"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2009.0051"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666180-00013"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00414.x"},{"key":"e_1_2_9_11_1","first-page":"15","article-title":"Buccal mucosa as a route for systemic drug delivery: a review","volume":"1","author":"Shojaei AH","year":"1998","journal-title":"J Pharm Pharm Sci"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/0044011-200929001-00002"},{"key":"e_1_2_9_13_1","volume-title":"Subsys (Fentanyl Sublingual Spray), CII [package insert]","year":"2014"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.683111"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2014.0212"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.02.017"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0079-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12225"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2006.0151"},{"key":"e_1_2_9_21_1","unstructured":"National Cancer Institute. Pain (PDQ\u00ae). May 3 2013.http:\/\/www.cancer.gov\/cancertopics\/pdq\/supportivecare\/pain\/HealthProfessional\/page1(accessed September 17 2013)."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24279"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e318209d320"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903336135"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(98)00179-1"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000210932.27945.4a"},{"key":"e_1_2_9_27_1","first-page":"327","article-title":"Fentanyl buccal tablet for relief of breakthrough pain in opioid\u2010tolerant patients with cancer\u2010related chronic pain","volume":"5","author":"Slatkin NE","year":"2007","journal-title":"J Support Oncol"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.07.028"},{"key":"e_1_2_9_29_1","unstructured":"US Food and Drug Administration.Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS). November 2013.http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM289730.pdf(accessed September 29 2014)."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00525.x"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpapr.12360","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.12360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T13:58:55Z","timestamp":1695736735000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.12360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,28]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/papr.12360"],"URL":"https:\/\/doi.org\/10.1111\/papr.12360","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,28]]}}}